<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336771">
  <stage>Registered</stage>
  <submitdate>6/04/2011</submitdate>
  <approvaldate>7/04/2011</approvaldate>
  <actrnumber>ACTRN12611000361909</actrnumber>
  <trial_identification>
    <studytitle>Does the anaesthetic drug propofol affect the blood levels of the endogenous cannabis-like substance anandamide?</studytitle>
    <scientifictitle>Effect of propofol on the peri-operative plasma level of the endogenous cannabinoid anandamide in patients undergoing minor elective surgery</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>peri-operative Anandamide Plasma Levels</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Maintenance of anaesthesia with intravenous propofol (target controlled infusion as clinically required: 4-6 mcg/ml)/fentanyl (as clinically required)</interventions>
    <comparator>Induction of anaesthesia with intravenous Thiopentone (3-5 mg/kg) and maintenance with sevoflurane (0.8-1.2 MAC)/fentanyl (as clinically required)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Anandamide Plasma levels</outcome>
      <timepoint>T0: Baseline (pre-operatively)
T1: 15 minutes after induction of anaesthesia
T2: 5 minutes after cessation of sevoflurane or propofol
T3: 25 minutes after T2
T4: 55 minutes after T2</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>nil</outcome>
      <timepoint>nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>patients scheduled for minor non-emergency surgery</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Age &lt; 18 yrs and &gt; 65 yrs, ASA physical status &gt; 2 (= significant comorbidity), history of chronic pain, a contraindication for any of the used drugs, and the incapacity to consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients are randomised into one of two groups: Propofol or Sevo. This is done via opening a sealed envelope directly prior to surgery.</concealment>
    <sequence>30 sealed envelopes containing information about the group allocation (either PROP or SEVO, n=15 each). 
Envelopes randomly mixed after sealing and numbered from 1-30
Envelopes drwan for randomisation in order of patients consented (e.g. patient 1 = envelope 1).
Seal broken directly prior to surgery.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>10/03/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Thomas Ledowski</primarysponsorname>
    <primarysponsoraddress>Royal Perth Hospital
Dept. of Anaesthesia
Wellington Street
Perth WA 6000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Prof. Kevin Croft</othercollaboratorname>
      <othercollaboratoraddress>Level 4 RPH MRF Building
Rear 50 Murray Street
Perth WA 6000</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Prof. Trevor Mori</othercollaboratorname>
      <othercollaboratoraddress>Level 4 RPH MRF Building
Rear 50 Murray Street
Perth WA 6000</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Prof. Anne Barden</othercollaboratorname>
      <othercollaboratoraddress>Level 4 RPH MRF Building
Rear 50 Murray Street
Perth WA 6000</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Anandamide is a body-own (endogenous) cannabis-like substance that is significantly involved in our response to stress, but also affects mood and has anti-nausea effects.
In the proposed project we will investigate the effect of the drugs propofol and sevoflurane (two of the most commonly used anaesthetic agents) on the blood concentration of the cannabis-like substance anandamide in 30 patients having an operation at Royal Perth Hospital.
In this trial, patients (15 each) will either receive an anaesthetic with propofol or with sevoflurane and we will measure the blood levels of anandamide by drawing blood (2x5ml) from a venous cannula anyway used to give the anaesthetic at 5 time points.
Results of this project will help us to understand significant positive side effects of propofol, such as its anti-nausea properties.</summary>
    <trialwebsite>nil</trialwebsite>
    <publication>not yet published</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>EC of the Royal Perth Hospital</ethicname>
      <ethicaddress>Colonial House
Royal Perth Hospital
Wellington Street
Perth WA 6000</ethicaddress>
      <ethicapprovaldate>14/02/2011</ethicapprovaldate>
      <hrec>EC 2010/096</hrec>
      <ethicsubmitdate>1/10/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Thomas Ledowski</name>
      <address>Royal Perth Hospital
Dept. of Anaesthesia
Wellington Street
Perth WA 6000</address>
      <phone>0061 8 9224 1037</phone>
      <fax />
      <email>thomas.ledowski@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Thomas Ledowski</name>
      <address>Royal Perth Hospital
Dept. of Anaesthesia
Wellington Street
Perth WA 6000</address>
      <phone>0061 8 9224 1037</phone>
      <fax>0061 8 9224 1111</fax>
      <email>thomas.ledowski@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>